1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection. 2010

R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
Univ of Pittsburgh Medical School, Pittsburgh, Pennsylvania, USA.

In summary, 1.7 years after transplantation, bortezomib rescue has been durably effective in salvaging our patient with refractory antibody mediated rejection. The only price has been persistently high levels of BK viruria. The presence of ongoing and even recurrent donor specific antibody has made it difficult to reduce immunosuppression further, and the concern that the high levels of BK viruria will eventually progress to viremia and nephropathy necessitates continued therapy with very low dose cidofovir and leflunomide. The absence of C1q binding DSA with stable renal function may provide some reserved optimism that the DSA that is detectable by convention Luminex assay may have reduced pathological implications. However, more data and prolonged follow-up are needed to determine whether or not non-complement binding DSA has an adverse pathological role.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D001739 BK Virus A species of POLYOMAVIRUS apparently infecting over 90% of children but not clearly associated with any clinical illness in childhood. The virus remains latent in the body throughout life and can be reactivated under certain circumstances. BK polyomavirus,Human Polyomavirus BK,Polyomavirus, BK,Polyomavirus hominis 1,Polyomavirus BK, Human
D001897 Boronic Acids Inorganic or organic compounds that contain the basic structure RB(OH)2. Boronic Acid,Acid, Boronic,Acids, Boronic
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft

Related Publications

R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
January 2009, Clinical transplants,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
October 2019, Transplantation direct,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
January 2010, Clinical transplants,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
December 2008, Transplantation,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
November 2016, Transplantation proceedings,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
March 2012, Clinical nephrology,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
January 2010, Clinical transplants,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
December 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
December 2018, HLA,
R Shapiro, and J Lunz, and A Zeevi, and A Basu, and M Mapara, and P Randhawa, and H P Tan, and V Sharma, and A Humar
September 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Copied contents to your clipboard!